Cargando…
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
OBJECTIVE: This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus...
Autores principales: | Lingvay, Ildiko, Brown‐Frandsen, Kirstine, Colhoun, Helen M., Deanfield, John, Emerson, Scott S., Esbjerg, Sille, Hardt‐Lindberg, Søren, Hovingh, G. Kees, Kahn, Steven E., Kushner, Robert F., Lincoff, A. Michael, Marso, Steven P., Fries, Tea Monk, Plutzky, Jorge, Ryan, Donna H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107832/ https://www.ncbi.nlm.nih.gov/pubmed/36502289 http://dx.doi.org/10.1002/oby.23621 |
Ejemplares similares
-
Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022) -
Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021) -
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021) -
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020) -
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)